CYBIN INC.
HELPHeld by 5 specialist biotech funds
High Convergence5 funds opened new positions. Next phase2 readout (Psilocybin): Mar 2023.
Cybin Inc. functions as a biopharmaceutical company currently in its clinical development phase, concentrating on the advancement of novel therapeutic agents derived from psychedelic compounds. Its research pipeline includes CYB003, a deuterated psilocybin analog under investigation for major depressive disorder, and CYB004, a deuterated DMT compound being developed to address generalized anxiety disorder.